Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Investing.com -- Sanofi (NASDAQ:SNY), the global healthcare leader, on Monday announced plans to acquire Blueprint Medicines (NASDAQ:BPMC).
Sanofi will pay $129.00 per share in cash at closing, which translates to an equity value of approximately $9.1 billion for Blueprint Medicines.
This move will extend Sanofi’s portfolio in the area of rare immunological diseases and add an early-stage pipeline in immunology.
The acquisition is planned to be financed through a combination of cash and new debt. Sanofi aims to finalize the deal in the third quarter of 2025.
The deal is expected to immediately increase Sanofi’s gross margin.
Blueprint shareholders are set to receive one non-tradeable Contingent Value Right (CVR).
This CVR will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR, respectively, upon the achievement of future development and regulatory milestones for BLU-808.
If these potential CVR payments are included, the total equity value of the Blueprint transaction represents approximately $9.5 billion on a fully diluted basis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.